A new GLP-1 drug, orforglipron, comes in pill form and appears to be roughly as effective as injected drugs like Ozempic.

Lilly trumpeted positive topline results from ACHIEVE-1 (NCT05971940) showing orforglipron to have met the trial’s primary endpoint of superior A1C reduction vs. placebo at 40 weeks.

The Rise of Weight Management Challenges in the Modern World Across the globe, millions of people are grappling with weight ...

Podcaster Joe Rogan recently stopped drinking alcohol, he announced on a recent episode of “The Joe Rogan Experience." ...

Dr. Mark Epstein, a plastic surgeon in New York, shared the most common procedures his male clients get, from filler to ...

In a trial, the daily GLP-1 pill showed "significant" results and similar side effects to injectable GLP-1 drugs like Ozempic and Mounjaro, the pharmaceutical company says.

Tirzepatide (Mounjaro) launched in India in March 2025, promising new hope for diabetes and obesity treatment. An expert ...

UK-based drug companies AstraZeneca and GSK could be affected by Trump’s next decision, as Karl Matchett reports ...

A daily pill from Eli Lilly lowered blood sugar levels and induced weight loss in people with Type 2 diabetes, the company ...

Skye Bioscience currently trades essentially at cash value, meaning investors who buy in today get a weight loss drug ...

Two common GLP-1 medications that are approved by the Food and Drug Administration (FDA) specifically for weight loss are ...

SYNT-101 offers a novel approach to weight loss by temporarily altering nutrient absorption in the small intestine. Unlike ...